PacBio said it expects new Vega shipments to offset year-over-year declines in Revio instrument sales—while currently installed Revios continue to bring in about $236,000 apiece in annual ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results , but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP loss of $0.20 per share was 15.5% below ...

Pacific Biosciences' Q4'24 results missed estimates. Growth in genetic data usage noted, but research funding uncertainties pose risks. See more on PACB stock here.

Gene sequencing equipment maker PacBio plans to cut around 120 jobs and lower expenses due to fresh tariffs and reduced funding for federal health agency National Institutes of Health (NIH), it ...

While Pacific Biosciences' earnings were beat, shrinking sales, high debt, and poor macro environment do not inspire confidence. Read why PACB is a Strong Sell.

PacBio said it is solidifying and expanding its distribution agreement with a local company, with plans to grow the footprint of its hi-fi long-read sequencers among both clinical and research labs.